Supplemental Table 1. Baseline characteristics of patient received TLC as first-line treatment.

|  |  |
| --- | --- |
| Characteristics | Number of patients (%)(N=65) |
| Median age (years, range) | 49 (26-73) |
| ECOG performance-status score012 | 35 (53.8)30 (46.2)0 (0.0) |
| Hormone receptor statusHR positiveHR negative | 21 (32.3)44 (67.7) |
| Disease-free intervalPrimary metastaticDFI≤1yearDFI>1year | 14 (21.5)21 (32.3)30 (46.2) |
| Metastatic sitesLungLiverBoneBrain | 20 (30.8)13 (20.0)17 (26.2)16 (24.6) |
| Number of metastatic sites12≥3 | 34 (52.3)16 (24.6)15 (23.1) |
| Visceral metastasesYesNo | 44 (67.7)21 (32.3） |
| Trastuzumab Resistance StatusResistanceRefractorinessUnknown | 11 (17.0)29 (44.6)25 (38.5) |
| Prior HER2-targeted therapyTrastuzumabLapatinibT-DM1Pertuzumab | 37 (56.9)0 (0.0)0 (0.0)0 (0.0) |

Abbreviations: HR, Hormone receptor; ECOG, Eastern Cooperative Oncology Group; DFI, Disease free interval; TLC, trastuzumab+ lapatinib+ chemotherapy

Supplemental Table 2. Baseline characteristics of patient received TLX after progressing on trastuzumab.

|  |  |
| --- | --- |
| Characteristics | Number of patients (%)(N=110) |
| Median age (years, range) | 52.5(29-87) |
| ECOG performance-status score012 | 39 (35.5)66 (60.0)5 (4.5) |
| Hormone receptor statusHR positiveHR negative | 44 (40.0)66 (60.0) |
| Disease-free intervalPrimary metastaticDFI≤1yearDFI>1year | 26 (23.6)19 (17.3)65 (59.1) |
| Metastatic sitesLungLiverBoneBrain | 38 (34.5)40 (36.4)49 (44.5)26 (23.6) |
| Number of metastatic sites12≥3 | 28 (25.5)36 (32.7)46 (41.8) |
| Visceral metastasesYesNo | 80 (72.7)30 (27.2) |
| Lines of advanced systematic therapy of TLC12≥3 | 19 (17.3)41 (37.3)50 (45.5) |
| Trastuzumab Resistance StatusResistanceRefractoriness | 45 (40.9)65 (59.1) |
| Prior HER2-targeted therapyTrastuzumabLapatinibT-DM1Pertuzumab | 110 (100.0)13 (11.8)1 (0.9)0 (0.0) |

Abbreviations: HR, Hormone receptor; ECOG, Eastern Cooperative Oncology Group; DFI, Disease free interval; TLX, trastuzumab+ lapatinib+ capecitabine

Supplemental Table 3. Objective response rate in patients received TLX.

|  |  |
| --- | --- |
| Response | Number of patients (%)(N=110) |
| Best response Complete responsePartial responseStable diseaseProgressive diseaseNAORR |  0 (0.0)34 (30.9)64 (58.2)8 (7.3)4 (3.6)34 (30.9)  |

Abbreviation: NA, not available; ORR: objective response rate; TLC, trastuzumab+ lapatinib+ capecitabine